Using the Lymph Node Ratio to Evaluate the Prognosis of Stage II/III Breast Cancer Patients Who Received Neoadjuvant Chemotherapy and Mastectomy / Journal of the Korean Cancer Association, 대한암학회지
Cancer Research and Treatment
; : 757-764, 2015.
Article
in English
| WPRIM (Western Pacific)
| ID: wpr-74288
Responsible library:
WPRO
ABSTRACT
PURPOSE:
This study was conducted to investigate the prognostic value of lymph node ratio (LNR) in stage II/III breast cancer patients who undergo mastectomy after neoadjuvant chemotherapy. MATERIALS ANDMETHODS:
Clinical and pathological data describing stage II/III breast cancer patients were included in this retrospective study. The primary outcomes were locoregional recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS).RESULTS:
Among 277 patients, there were 43 ypN0, 64 ypN1, 89 ypN2, and 81 ypN3 cases. Additionally, there were 43, 57, 92 and 85 cases in the LNR 0, 0.01-0.20, 0.21-0.65, and > 0.65 groups, respectively. The median follow-up was 49.5 months. Univariate analysis showed that both ypN stage and LNR were prognostic factors of LRFS, DMFS, DFS, and OS (p 0.05).CONCLUSION:
The integrated use of LNR and ypN may be suitable for evaluation the prognosis of stage II/III breast cancer patients who undergo mastectomy after neoadjuvant chemotherapy.
Full text:
Available
Database:
WPRIM (Western Pacific)
Main subject:
Prognosis
/
Breast
/
Breast Neoplasms
/
Multivariate Analysis
/
Retrospective Studies
/
Follow-Up Studies
/
Disease-Free Survival
/
Neoadjuvant Therapy
/
Drug Therapy
/
Lymph Nodes
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Cancer Research and Treatment
Year:
2015
Document type:
Article